

COMMUNICATIONS TO THE EDITOR

Total Synthesis of a Tetracyclic Anti-tumor, UCE6

Sir:

A tetracyclic compound, UCE6 (**1**) was isolated from fermentation broth of actinomycetes strain UOE6 to show strong anti-tumor activities.¹⁾ The structure **1** was determined mainly by NMR studies to have a tetracyclic skeleton, although the absolute configuration remained undetermined.²⁾

Herein, we describe the first total synthesis of (\pm)-UCE6 (**1**).


From the retrosynthetic perspective (Fig. 1), the tetracyclic skeleton is expected to be accessible by the tandem Michael-Dieckmann type reaction³⁾ of the

benzofuranone **2** with the cyclic α,β -unsaturated ketone **3**. The former **2** is derived from 2-methylresorcinol (**4**).⁴⁾ The other **3** may be prepared by [4+2] cycloaddition reaction of 2-cyclohexen-1-one (**5**) with the diene **6**.


Methoxymethylation of **4** followed by amidation and formylation gave the aldehyde **7** (Scheme 1). Reaction of **7** with PhSO_2Na gave a mixture of deprotected products, which again methoxymethylated to the desired segment **2** in a moderate yield.

The diene **6** was prepared from 1,2,4-trihydroxybutane (**8**) in 4 steps: 1) NaIO_4 oxidative cleavage; 2) Wittig reaction; 3) *O*-benzoylation; 4) enol phosphate formation (Scheme 2). Cycloaddition of **6** with 2-cyclohexen-1-one (**5**) proceeded smoothly by aid of $\text{BF}_3 \cdot \text{Et}_2\text{O}$ to give a diastereomeric mixture of the adduct **9**. The $^1\text{H-NMR}$ studies showed the adduct to be a 3 : 1 mixture due to the C-

Fig. 1.




Scheme 1.




Conditions; (a) MOMCl, NaH/DMF, 0°C to rt, 0.5 hour; 87% (b) ClCONEt_2 , *s*-BuLi/THF, -78°C to rt, 0.5 hour; 78% (c) DMF, *s*-BuLi, TMEDA/THF, -78°C to rt, 0.5 hour; 82% (d) $\text{PhSO}_2\text{Na}/\text{AcOH}$, 80°C, 16 hours; 66% (e) MOMCl, *i*-Pr₂NEt/DMF, -40°C to rt, 0.5 hour; 74%.

Scheme 2.



Conditions; (a) $\text{NaIO}_4/\text{H}_2\text{O}$, 0°C , 5 minutes (b) $\text{Ph}_3\text{P}=\text{CHCOMe}$, $\text{NaOAc}/\text{CHCl}_3\text{-H}_2\text{O}$, rt, 12 hours (c) BzCl , $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$, rt, 12 hours; 58% in 3 steps (d) $\text{ClPO}(\text{OEt})_2$, $\text{LiN}(\text{TMS})_2/\text{THF}$, -78°C to rt, 10 minutes; 79% (e) 2-cyclohexen-1-one (**5**), $\text{BF}_3\cdot\text{Et}_2\text{O}/\text{PhMe}$, rt, 12 hours; 64% (f) PhSeCl , $\text{LiN}(\text{TMS})_2/\text{THF}$, rt, 5 minutes (g) 30% H_2O_2 , aq. $\text{NaHCO}_3/\text{CH}_2\text{Cl}_2$, rt, 36 hours; 68% in 2 steps (h) NaBH_4 , $\text{CeCl}_3\cdot 7\text{H}_2\text{O}$, NaOEt/EtOH , 0°C to 40°C , 12 hours; 81% (i) $(\text{COCl})_2$, DMSO , $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$, -78°C to rt, 1 hour; 86% (j) MeMgBr/THF , -10°C , 1 hour; 81% (k) *o*-iodoxybenzoic acid/ PhMe - DMSO , rt, 3 hours; 84% (l) MeCHO , Ipc_2BCl , $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$, -78°C to rt, 4 hours; 85% (m) $\text{BnOC}(\text{=NH})\text{CCl}_3$, $\text{TMSOTf}/\text{CH}_2\text{Cl}_2\text{-cyclohexane}$, rt, 2 hours; 75% (n) 1,2-bis(trimethylsilyloxy)ethane, $\text{TMSOTf}/\text{CH}_2\text{Cl}_2$, -78°C to 0°C , 1 hour; 75%.

Scheme 3.



Conditions; (a) $\text{LiN}(\text{TMS})_2/\text{THF}$, -78°C to 60°C , 2 hours (b) Pd-C , BnOMe/PhMe , 110°C , 15 hours; 64% in 2 steps (c) $t\text{-BuOK}$, $\text{H}_2\text{O}/t\text{-BuOH}$, 60°C , 15 minutes; 85% (d) H_2 , $\text{Pd}(\text{OH})_2\text{-C}/1,4\text{-dioxane}$, rt, 2 hours; 90% (e) $\text{LiBF}_4/\text{THF-MeCN-H}_2\text{O}$, 70°C , 72 hours; 76%.

Table 1-1. Physico-chemical properties of compounds.

Compds.	Mp (°C)	¹ H-NMR (400, 500 or 600 MHz; δ ppm; <i>J</i> Hz) IR(KBr; cm ⁻¹) FAB-MS (<i>m/z</i>)
1	>300 (decomp.) red solid (THF)	¹ H-NMR(CD ₃ CO ₂ D): δ 1.28(3H, d, <i>J</i> =6.0), 2.19(3H, s), 2.89(1H, dd, <i>J</i> =17.0&4.0), 2.99(1H, dd, <i>J</i> =17.0&8.0), 4.09-4.14(1H, m), 4.42(1H, d, <i>J</i> =17.0), 4.47(1H, d, <i>J</i> =17.0), 7.05(1H, d, <i>J</i> =2.0), 7.32(1H, d, <i>J</i> =2.0), 7.36(1H, s), 8.11(1H, s) IR(KBr): 1697, 1655, 1604, 1442, 1377, 1329, 1278, 1218 FAB-MS: 437(M+H) ⁺
2	119 prisms (hexane-acetone)	¹ H-NMR(CDCl ₃): δ 2.12(3H, s), 3.51(3H, s), 3.52(3H, s), 5.03(1H, d, <i>J</i> =7.0), 5.27(1H, d, <i>J</i> =7.0), 5.31(1H, d, <i>J</i> =7.0), 5.45(1H, d, <i>J</i> =7.0), 6.01(1H, s), 7.34(1H, s), 7.51(2H, dd, <i>J</i> =8.0&8.0), 7.66(1H, dddd, <i>J</i> =8.0, 8.0, 1.0&1.0), 7.83(2H, dd, <i>J</i> =8.0&1.0) FAB-MS: 409(M+H) ⁺
3a¹⁾	oil	¹ H-NMR(CDCl ₃): δ 1.17, 1.18(1:1, 3H in total, each d, <i>J</i> =6.0), 1.31-1.38(6H, m), 1.86-1.94(1H, m), 2.01-2.08(1H, m), 2.14-2.36(7H, m), 2.46-2.54(1H, m), 2.85 (1H, br s), 3.80-4.01(5H, m), 4.09-4.20(4H, m), 4.50-4.58(2H, m), 5.83(1H, br s), 5.98, 5.99(1:1, 1H in total, each d, <i>J</i> =10.0), 6.83-6.89(1H, m), 7.28-7.38(5H, m) FAB-MS: 535(M+H) ⁺
6	oil	¹ H-NMR(CDCl ₃): δ 1.33(6H, dt, <i>J</i> =7.0&1.0), 2.61(2H, ddt, <i>J</i> =7.0, 7.0&1.0), 4.16(2H, ddq, <i>J</i> =10.0, 8.0&7.0), 4.18(2H, ddq, <i>J</i> =10.0, 8.0&7.0), 4.39(2H, t, <i>J</i> =7.0), 4.78(1H, dd, <i>J</i> =2.0&2.0), 5.02(1H, dd, <i>J</i> =2.0&2.0), 6.03(1H, ddt, <i>J</i> =15.0, 2.0&1.0), 6.11(1H, dt, <i>J</i> =15.0&7.0), 7.44(2H, dd, <i>J</i> =8.0&7.5), 7.56(1H, dddd, <i>J</i> =7.5, 7.5, 1.0&1.0), 8.03(2H, dd, <i>J</i> =8.0&1.0) FAB-MS: 355(M+H) ⁺
7	oil	¹ H-NMR(CDCl ₃): δ 1.03(3H, t, <i>J</i> =7.0), 1.30(3H, t, <i>J</i> =7.0), 2.29(3H, s), 3.10(1H, dq, <i>J</i> =7.0&7.0), 3.14(1H, dq, <i>J</i> =7.0&7.0), 3.50(3H, s), 3.57(3H, s), 3.61(2H, q, <i>J</i> =7.0), 5.02(1H, d, <i>J</i> =6.0), 5.08(1H, d, <i>J</i> =6.0), 5.26(1H, d, <i>J</i> =7.0), 5.28(1H, d, <i>J</i> =7.0), 7.43(1H, s), 9.91(1H, s) FAB-MS: 340(M+H) ⁺
9	oil	¹ H-NMR(CDCl ₃): δ 1.06-1.12(6H, m), 1.20-2.28(13H, m), 3.96-4.09(4H, m), 4.16-4.26, 4.36-4.43(3:1, 2H in total, each m), 5.69, 5.73(1:3, 1H in total, each br s), 7.05-7.14(3H, m), 8.16, 8.26(3:1, 2H in total, each d, <i>J</i> =7.0) FAB-MS: 451(M+H) ⁺
11	oil	11a: ¹ H-NMR(CDCl ₃): δ 1.36(6H, br t, <i>J</i> =7.0), 2.15-2.42(5H, m), 2.49-2.58(2H, m), 3.05-3.10(1H, m), 3.18(1H, br s), 4.12-4.19(4H, m), 5.36(1H, br s), 6.01(1H, ddd, <i>J</i> =10.0, 2.0&0), 6.92(1H, ddd, <i>J</i> =10.0, 6.0&2.0), 9.81(1H, s) 11b: ¹ H-NMR(CDCl ₃): δ 1.34(6H, dt, <i>J</i> =7.0&1.0), 2.16-2.57(6H, m), 2.63-2.72(2H, m), 3.35(1H, br s), 4.08-4.20(4H, m), 5.45(1H, br s), 5.98(1H, ddd, <i>J</i> =10.0, 2.0&2.0), 6.89(1H, ddd, <i>J</i> =10.0, 4.0&4.0), 9.74(1H, s) FAB-MS: 343(M+H) ⁺
12a¹⁾	oil	¹ H-NMR(CDCl ₃): δ 1.34(3H, dt, <i>J</i> =7.0&1.0), 1.35(3H, dt, <i>J</i> =7.0&1.0), 2.13-2.33(4H, m), 2.15(3H, s), 2.36(1H, dddd, <i>J</i> =11.0, 11.0, 1.0&1.0), 2.42(1H, dd, <i>J</i> =17.0&9.0), 2.52(1H, ddd, <i>J</i> =19.0, 6.0&4.0), 3.08(1H, br s), 3.16(1H, dd, <i>J</i> =17.0&3.0), 4.10-4.18(4H, m), 5.35(1H, br s), 5.99(1H, ddd, <i>J</i> =10.0, 2.0&0), 6.90(1H, ddd, <i>J</i> =10.0, 6.0&2.0) FAB-MS: 357(M+H) ⁺

Table 1-2. Continued.

Compds.	Mp (°C)	¹ H-NMR (300, 400 or 600 MHz; δ ppm; J Hz) IR(KBr; cm ⁻¹) FAB-MS (m/z)
13a ¹⁾	oil	¹ H-NMR(CDCl ₃): δ 1.18, 1.19(1:1, 3H in total, each d, J=6.0), 1.31-1.37(6H, m), 2.21-2.36(3H, m), 2.52(1H, dd, J=17.0&9.0), 2.60, 2.61(1:1, 1H in total, each dd, J=17.0&3.0), 2.68-2.78(2H, m), 2.84, 2.90(1:1, 1H in total, each dd, J=18.0&7.0), 2.95(1H, ddd, J=17.0, 4.0&4.0), 3.05(1H, br s), 3.33, 3.37(1:1, 1H in total, each dd, J=18.0&7.0), 4.08-4.27(5H, m), 5.31(1H, br s), 5.86-5.89(1H, m), 6.71-6.76(1H, m) FAB-MS: 401(M+H) ⁺
14	orange wax	¹ H-NMR(CDCl ₃): δ 1.30(3H, d, J=6.0), 1.40(6H, dt, J=7.0&1.0), 1.86(1H, dd, J=14.0&5.0), 2.21-2.25(1H, m), 2.26(3H, s), 3.34-3.38(1H, m), 3.40-3.44(1H, m), 3.53(3H, s), 3.70-3.74(2H, m), 3.84-3.90(1H, m), 3.98(1H, d, J=14.0), 4.05(1H, d, J=14.0), 4.25-4.32(4H, m), 4.51(1H, d, J=12.0), 4.59(1H, d, J=12.0), 5.40(2H, s), 7.28-7.32(3H, m), 7.34-7.37(2H, m), 7.45(1H, d, J=2.0), 7.61(1H, s), 7.69(1H, d, J=2.0), 8.17(1H, s), 12.62(1H, s), 14.96(1H, s) FAB-MS: 751(M+H) ⁺
15	219-221 (decomp.) orange solid (acetone)	¹ H-NMR[(CD ₃) ₂ CO]: δ 1.25(3H, d, J=6.0), 1.83(1H, dd, J=14.0&6.0), 2.20(1H, dd, J=14.0&6.0), 2.22(3H, s), 3.48-3.60(2H, m), 3.52(3H, s), 3.77-3.82(2H, m), 3.85(1H, tq, J=6.0&6.0), 3.96(1H, d, J=14.0), 4.01(1H, d, J=14.0), 4.47(1H, d, J=12.0), 4.55(1H, d, J=12.0), 5.49(2H, s), 7.18(1H, dd, J=7.0&7.0), 7.26(2H, dd, J=7.0&7.0), 7.29(1H, d, J=2.0), 7.32(2H, d, J=7.0), 7.36(1H, d, J=2.0), 7.60(1H, s), 8.03(1H, s), 9.58(1H, br s), 12.68(1H, s), 15.01(1H, br s) FAB-MS: 615(M+H) ⁺
16	160 red solid (MeOH)	¹ H-NMR[(CD ₃) ₂ CO]: δ 1.09(3H, d, J=6.0), 1.85-1.88(2H, m), 2.22(3H, s), 3.56-3.64(2H, m), 3.57(3H, s), 3.84-3.92(3H, m), 4.01-4.08(1H, m), 4.08-4.14(1H, m), 5.49(2H, s), 7.25(1H, br s), 7.36(1H, br s), 7.59(1H, s), 8.01(1H, s), 12.70(1H, br s), 15.03(1H, br s) FAB-MS: 525(M+H) ⁺

1) The ¹H-NMR spectra of **3b**, **12b** and **13b** are very similar to those of **3a**, **12a** and **13a**, respectively.

8 position, because the stereochemistry between C-4a and C-8a was presumed to be *cis* according to experimental facts.⁵⁾ The mixture was led to the enone **10** by phenylselenylation and H₂O₂ oxidation. Hydride reduction of **10** with de-*O*-benzoylation was followed by oxidation to afford a 3:1 mixture of the aldehyde **11**, which was isolated by silica-gel column chromatography (toluene-acetone 3:1) to give **11a** [the major product: Rf 0.45 on TLC (toluene-acetone 1:1)] and **11b** (the minor: Rf 0.40). Direct de-*O*-benzoylation of **10** gave no desired product. The *C*-methyl group was introduced onto the aldehydes **11a** and **11b** by Grignard reaction and the resulting alcohols were oxidized⁶⁾ to the corresponding methyl ketones **12a** and **12b**, respectively. While all the asymmetric centers at C-4a, C-8 and C-8a disappeared by aromatization on the

later stage (**3**→**14**), all isomers were isolated and used for the next step to obtain the optically active products. Each compound **12a** and **12b** was treated with acetaldehyde in the presence of optically active diisopinocampheylchloroborane (Ipc₂BCl)⁷⁾ to give the alcohol **13a** and **13b**, respectively, each of which was a 1:1 diastereomeric mixture due to the newly produced asymmetric center. Although many kinds of enantioselective aldol reaction conditions were tested,⁸⁾ the optically active UCE6 (**1**), which could be finally derived from the product **13a** or **13b**, was not obtained. However, only the use of Ipc₂BCl gave a fairly good yield of diastereomers **13a** and **13b**, which were converted into **3a** and **3b**, respectively, by *O*-benzoylation and ethylene acetal formation.

With **2** and **3** in hand, we turned to the tandem Michael-

Dieckmann type reaction³⁾ (Scheme 3). The coupling was effectively carried out by treatment with $\text{LiN}(\text{TMS})_2$ to yield the tetracyclic product, which was aromatized to the racemic alcohol **14** as a single product under mild oxidation conditions by reduction of benzyl methyl ether in the presence of Pd-C. One of the two *O*-MOM groups was recognized to be readily removed by the effect of the quinone carbonyl group. De-*O*-phosphonation of **14** to give **15** was followed by removal of *O*-benzyl group to produce quantitatively **16**. Finally, all protective groups of **16** were removed to give the desired product, UCE6 (**1**), which was identical in all respects with the natural product.⁹⁾

Acknowledgment

We are grateful to Advanced Research Institute for Science and Engineering, Waseda University, and High-Tech Research Center Project the Ministry of Education, Science, Sports and Culture for the generous support of our program. The present work was financially supported by Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture.

KUNIAKI TATSUTA*
TAKAYUKI INUKAI
SAYAKA ITOH
MASATAKA KAWARASAKI
YUKO NAKANO

Department of Applied Chemistry,
School of Science and Engineering,
Waseda University
3-4-1 Ohkubo, Shinjuku, Tokyo 169-8555, Japan

(Received August 5, 2002)

References

- 1) FUJII, N.; F. TANAKA, Y. YAMASHITA, T. ASHIZAWA, S. CHIBA & H. NAKANO: UCE6, a new antitumor antibiotic with topoisomerase I-mediated DNA cleavage activity produced by actinomycetes: producing organism, fermentation, isolation and biological activity. *J. Antibiotics* 50: 490~495, 1997
- 2) FUJII, N.; Y. YAMASHITA, S. CHIBA, Y. UOSAKI, Y. SAITOH, Y. TUJI & H. NAKANO: UCE6, a new antitumor antibiotic with topoisomerase I mediated DNA cleavage activity, from actinomycetes. *J. Antibiotics* 46: 1173~1174, 1993
- 3) TATSUTA, K.: Total syntheses of useful bioactive compounds. *Adv. Synth. Catal.* 343: 143~159, 2001
- 4) KELLY, T. R.; S. H. BELL, N. OHASHI & R. J. ARMSTRONG-CHONG: Synthesis of (\pm)-fredericamycin A. *J. Am. Chem. Soc.* 110: 6471~6480, 1988
- 5) LIU, H.-J.; T. K. NGOOI & E. N. C. BROWNE: Diels-Alder reactions of 2-carbomethoxy-2-cyclohexen-1-one. *Can. J. Chem.* 66: 3143~3152, 1988
- 6) NICOLAOU, K. C.; Y.-L. ZHONG & P. S. BARAN: A new method for the one-step synthesis of α,β -unsaturated carbonyl systems from saturated alcohols and carbonyl compounds. *J. Am. Chem. Soc.* 122: 7596~7597, 2000
- 7) PATERSON, I.; J. M. GOODMAN, M. A. LISTER, R. C. SCHUMANN, C. K. MCCLURE & R. D. NORCROSS: Enantio- and diastereoselective aldol reactions of achiral ethyl and methyl ketones with aldehydes: the use of enol diisopinocampheylborinates. *Tetrahedron* 46: 4663~4684, 1990
- 8) NELSON, S. G.: Catalyzed enantioselective aldol additions of latent enolate equivalents. *Tetrahedron: Asymmetry* 9: 357~389, 1998
- 9) An authentic sample of natural UCE6 was kindly provided by Dr. Y. KANDA, Kyowa Hakko Kogyo Co., Ltd.

* Corresponding author: tatsuta@mn.waseda.ac.jp